BROADWOOD PARTNERS, L.P. 13D and 13G filings for Lineage Cell Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-28 8:07 pm Purchase | 2025-01-27 | 13D | Lineage Cell Therapeutics, Inc. LCTX | BROADWOOD PARTNERS, L.P. | 57,848,357 24.500% | 15,789,474 (+37.54%) | Filing |
| 2024-11-21 8:05 pm Purchase | 2024-11-19 | 13D | Lineage Cell Therapeutics, Inc. LCTX | BROADWOOD PARTNERS, L.P. | 42,058,883 19.100% | 75,000 (+0.18%) | Filing |
| 2024-02-08 6:57 pm Purchase | 2024-02-06 | 13D | Lineage Cell Therapeutics, Inc. LCTX | BROADWOOD PARTNERS, L.P. | 41,983,883 22.200% | 6,756,610 (+19.18%) | Filing |
| 2022-03-25 5:23 pm Purchase | 2022-03-10 | 13D | Lineage Cell Therapeutics, Inc. LCTX | BROADWOOD PARTNERS, L.P. | 35,227,273 20.700% | 980,106 (+2.86%) | Filing |
| 2021-03-16 5:04 pm Purchase | 2021-03-11 | 13D | Lineage Cell Therapeutics, Inc. LCTX | BROADWOOD PARTNERS, L.P. | 34,247,167 21.200% | 34,247,167 (New Position) | Filing |